PT - JOURNAL ARTICLE AU - Ashraful Haque AU - David G. Kiely AU - Gabor Kovacs AU - A.A. Roger Thompson AU - Robin Condliffe TI - Pulmonary hypertension phenotypes in patients with systemic sclerosis AID - 10.1183/16000617.0053-2021 DP - 2021 Sep 30 TA - European Respiratory Review PG - 210053 VI - 30 IP - 161 4099 - http://err.ersjournals.com/content/30/161/210053.short 4100 - http://err.ersjournals.com/content/30/161/210053.full SO - EUROPEAN RESPIRATORY REVIEW2021 Sep 30; 30 AB - Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting from a pulmonary arterial vasculopathy, PH due to left heart disease and PH due to interstitial lung disease. The incidence of pulmonary veno-occlusive disease is also increased. Accurate and early diagnosis to allow optimal treatment is, therefore, essential. Recent changes to diagnostic haemodynamic criteria at the 6th World Symposium on Pulmonary Hypertension have resulted in therapeutic uncertainty regarding patients with borderline pulmonary haemodynamics. Furthermore, the optimal pulmonary vascular resistance threshold for diagnosing PAH and the role of exercise in identifying early disease require further elucidation. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with SSc.Different forms of pulmonary hypertension can be present in patients with systemic sclerosis. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with systemic sclerosis. https://bit.ly/3xUwrVB